You are here: Home » Current Affairs » Coronavirus » News
Business Standard

Suspect profit, political gains took precedence over science: Experts body

In a statement, the Progressive Medicos and Scientists Forum said India was quick to criticise China and Russia for granting emergency approvals to vaccines without efficacy data

Topics
Coronavirus | Coronavirus Vaccine | Coronavirus Tests

Press Trust of India  |  New Delhi 

Coronavirus Vaccine
The Drugs Controller General of India (DCGI) had on Sunday approved Oxford Covid-19 vaccine Covishield, manufactured by the Serum Institute, and indigenously developed Covaxin of Bharat Biotech for restricted emergency use

Days after two Covid-19 vaccines were granted restricted emergency use approval by India's drug regulator, a national association of doctors and scientists on Tuesday said they suspect "profit and political gains took precedence over science".

In a statement, the Progressive Medicos and Scientists Forum said India was quick to criticise China and Russia for granting emergency approvals to vaccines without efficacy data, but it "failed to exercise diligence when its turn arrived".

"There are many reasons to suspect that profit and political gains have taken precedence over science," the Progressive Medicos and Scientists Forum said.

The Drugs Controller General of India (DCGI) had on Sunday approved Oxford Covid-19 vaccine Covishield, manufactured by the Serum Institute, and indigenously developed Covaxin of Bharat Biotech for restricted emergency use in the country, paving the way for a massive inoculation drive.

Industry experts and some opposition leaders have expressed concern over the absence of Phase 3 trial data on Covaxin. The critics have cautioned that "sidestepping" processes and giving "premature" clearance could risk lives and fuel vaccine hesitancy in India.

However, Bharat Biotech has rejected criticism over the grant of emergency use authorisation by India's drug regulator to its COVID-19 vaccine, asserting it has a track record of producing safe and efficacious vaccines and has been transparent with all data.

Krishna Ella, chairman of Bharat Biotech, said the company has done "200 per cent honest clinical trials" and yet it was receiving "backlash".

Covaxin addresses an unmet medical need and has generated excellent safety data with a robust immune response to multiple viral proteins that persist, Ella has said.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)


(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Tue, January 05 2021. 21:03 IST
RECOMMENDED FOR YOU